Mod GRF / Ipamorelin / GHRP-2 Blend
Mod GRF / Ipamorelin / GHRP-2 Blend research profile covering evidence quality, proposed mechanisms, safety considerations, regulatory status, and linked…
Evidence-led profile
Research snapshot
- Evidence stage
- Emerging research
- Editorial review
- Mar 8, 2026
Published by the PepGuide Editorial Team using our research methodology.
This triple-peptide blend combines Mod GRF 1-29 (Modified Growth Hormone Releasing Factor), a tetrasubstituted GHRH analogue with improved metabolic stability, with two growth hormone secretagogues: Ipamorelin and GHRP-2. Mod GRF 1-29 activates pituitary GHRH receptors to promote pulsatile GH release, while Ipamorelin and GHRP-2 act on the ghrelin receptor (GHS-R1a) to amplify GH output through a separate signaling pathway.
Mechanism of Action
Synergistic Triple-Peptide Design
This blend combines three complementary growth hormone secretagogues that act through distinct but converging mechanisms at the hypothalamic-pituitary axis:
- Modified GRF 1-29 (Mod GRF, CJC-1295 without DAC) — a stabilized analog of growth hormone-releasing hormone (GHRH) residues 1-29
- Ipamorelin — a selective pentapeptide ghrelin mimetic
- GHRP-2 (pralmorelin) — a potent hexapeptide growth hormone releasing peptide
GHRH Receptor Pathway (Mod GRF 1-29)
Modified GRF 1-29 binds the GHRH receptor (GHRHR) on anterior pituitary somatotrophs, activating Gs-coupled adenylyl cyclase signaling. This elevates intracellular cAMP, activates protein kinase A (PKA), and phosphorylates CREB to drive GH gene transcription (GH1) and prime somatotroph secretory vesicles for exocytosis. The amino acid substitutions at positions 2, 8, 15, and 27 confer resistance to DPP-IV cleavage, extending the effective half-life compared to native GHRH.
GHS-R1a Pathway (Ipamorelin & GHRP-2)
Both Ipamorelin and GHRP-2 activate the growth hormone secretagogue receptor type 1a (GHS-R1a), the endogenous ghrelin receptor, on pituitary somatotrophs. This triggers Gq-coupled phospholipase C (PLC) signaling, generating IP3 and DAG, mobilizing intracellular calcium from the endoplasmic reticulum, and activating protein kinase C (PKC). The resulting calcium influx directly triggers GH vesicle exocytosis.
Complementary Mechanisms of GHRP-2
GHRP-2 provides additional hypothalamic-level effects not shared by Ipamorelin: it stimulates endogenous GHRH release from arcuate nucleus neurons and functionally suppresses somatostatin release from periventricular neurons. This dual hypothalamic action creates a permissive environment for maximal GH pulse amplitude. GHRP-2 also mildly stimulates ACTH, cortisol, and prolactin release — effects largely absent with the more selective Ipamorelin.
Synergistic Amplification
The combination of GHRH-pathway (cAMP/PKA) and ghrelin-pathway (PLC/PKC/Ca2+) activation produces synergistic GH release that exceeds the sum of individual peptide effects. This mirrors the physiological interplay between endogenous GHRH and ghrelin, where concurrent stimulation amplifies GH pulse amplitude 5-10 fold compared to either signal alone. The triple combination maximizes this synergy while GHRP-2's somatostatin-suppressing action extends the secretory window.
Safety and Limitations
This blend combines multiple growth hormone secretagogues, and side effects can include transient injection site reactions, flushing, and water retention. The GHRP-2 component can increase appetite and may transiently elevate cortisol and prolactin levels. As with any GH-elevating therapy, there are theoretical concerns about effects on insulin sensitivity and the growth of pre-existing neoplasms.
Research protocol summary
- Route
- Subcutaneous injection
These values summarize cataloged research protocols. They are not personal dosing instructions or medical guidance.
Reconstitution Calculator
Pharmacokinetic Profile
Mod GRF / Ipamorelin / GHRP-2 Blend — Pharmacokinetic Curve
Subcutaneous injectionResearch Protocols
subcutaneous Injection
Administered via subcutaneous injection.
Reported Research Timeline
Rapid onset expected; half-life of Mod GRF 1-29: ~30 min; Ipamorelin: ~2 hr; GHRP-2: ~1-2 hr indicates fast-acting pharmacokinetics
Due to short half-life (Mod GRF 1-29: ~30 min; Ipamorelin: ~2 hr; GHRP-2: ~1-2 hr), effects are expected per-dose; consistent daily administration...
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Continue researching Mod GRF / Ipamorelin / GHRP-2 Blend
Keep scientific evidence separate from commercial availability. Review how claims are evaluated, explore question-led research paths, or inspect disclosed source records without changing the editorial conclusions on this page.